Olanzapine for Stomach Cancer

This trial tests whether low-dose olanzapine can help patients with stomach cancer maintain weight, improve appetite, and enhance nutritional health during chemotherapy. Patients will receive either standard chemotherapy alone or with olanzapine, a medication typically used for mental health, to determine its potential benefits. The trial targets patients with confirmed stomach cancer who are about to begin chemotherapy and surgery. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, providing an opportunity to benefit from an innovative approach.

The trial does not specify if you need to stop taking your current medications. However, you will continue to receive standard chemotherapy treatments, so it's best to discuss your current medications with the trial team.

Research has shown that olanzapine is generally safe for people. Studies have found that it can help increase appetite and improve the quality of life for patients with stomach cancer. Specifically, patients taking olanzapine reported less nausea and vomiting compared to those who did not take it, suggesting that the drug might help manage some chemotherapy side effects.

Evidence also indicates that even a low dose of olanzapine, such as 2.5 mg per day, can prevent chemotherapy-induced nausea and vomiting. Importantly, studies have not identified any major side effects with this dosage. In fact, patients taking olanzapine experienced fewer severe side effects than those not taking the drug, supporting the idea that olanzapine is safe in this context.

Researchers are excited about using olanzapine for stomach cancer because it offers a new approach by potentially enhancing the effects of standard chemotherapy. Unlike traditional treatments that focus solely on attacking cancer cells, olanzapine, typically used to treat psychiatric conditions, might help improve the body's response to chemotherapy, potentially leading to better outcomes. By combining olanzapine with standard chemotherapy, there is hope that this could lead to more effective treatment regimens, improving survival rates and quality of life for patients.

Research has shown that olanzapine is primarily used to treat mental health conditions such as schizophrenia and bipolar disorder by balancing brain chemicals like dopamine and serotonin. Although olanzapine is not specifically approved for stomach cancer treatment, researchers are interested in its potential to alleviate symptoms like weight loss and appetite issues in cancer patients. In other contexts, olanzapine has helped individuals gain weight and improve appetite. In this trial, one group of participants will receive neoadjuvant chemotherapy with olanzapine to explore its potential benefits in maintaining weight and nutrition during treatment. However, its use for stomach cancer patients remains under study, and more evidence is needed to confirm its effectiveness.⁶⁷⁸⁹¹⁰